Treatment of Chronic Fungal Vaginitis

Initial Diagnostic Confirmation

The Centers for Disease Control and Prevention recommends obtaining vaginal cultures to confirm the clinical diagnosis and identify non-albicans species, particularly Candida glabrata, which occurs in 10-20% of recurrent cases and responds poorly to conventional azole therapy 1, 2
Vaginal cultures can help identify C. glabrata, which does not form pseudohyphae or hyphae and is not easily recognized on microscopy 1, 2

The Centers for Disease Control and Prevention recommends extended-duration initial therapy with topical azole for 7-14 days or fluconazole 150 mg oral dose repeated 3 days later to achieve mycologic remission 1, 2
For severe vulvovaginitis, the Centers for Disease Control and Prevention recommends using 7-14 days of topical azole or 150 mg fluconazole 2

The Centers for Disease Control and Prevention recommends initiating maintenance therapy for 6 months after achieving mycologic remission, with options including fluconazole 100-150 mg once weekly, clotrimazole 500 mg vaginal suppository once weekly, ketoconazole 100 mg once daily, or itraconazole 400 mg once monthly or 100 mg once daily 2
Suppressive maintenance therapies can reduce recurrence effectively, but 30-40% of women will have recurrent disease once maintenance therapy is discontinued 2

For C. glabrata or other non-albicans species that fail conventional azole therapy, consider alternative agents like boric acid 600 mg gelatin capsules intravaginally daily for 14 days or topical nystatin 4

The Centers for Disease Control and Prevention recommends that treatment of sexual partners is NOT routinely recommended, as VVC is not typically sexually transmitted, but male partners with symptomatic balanitis may benefit from topical antifungal treatment 1, 2, 4

Patients should return if symptoms persist or recur within 2 months, and for women on long-term ketoconazole, monitor for hepatotoxicity 1, 2, 4
Surveillance of recurrent isolates for azole resistance development is prudent, though resistance remains rare 2

The Centers for Disease Control and Prevention recommends avoiding short-course therapy for recurrent disease, as this is only appropriate for uncomplicated acute episodes 1, 2, 5
Do not skip the induction phase, as jumping directly to maintenance therapy without achieving mycologic remission first leads to treatment failure 1, 2